Literature DB >> 29344182

C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer.

Minjie Mao1, Xiaoli Wei2, Hui Sheng3, Peidong Chi1, Yijun Liu1, Xiaoyan Huang4, Yifan Xiang4, Qianying Zhu1, Shan Xing1, Wanli Liu1.   

Abstract

Multiple studies have reported the prognostic association of certain inflammatory factors with various types of cancer. The present study assessed the prognostic value of the C-reactive protein (CRP)/albumin (Alb) ratio and the neutrophil/lymphocyte ratio (NLR), separately and in combination, in gastric cancer (GC). A total of 337 cases pathologically diagnosed with gastric adenocarcinoma were retrospectively evaluated. The clinicopathological and prognostic relevance of the CRP/Alb ratio and NLR and their combination were analyzed. The optimal cut-off values of the CRP/Alb ratio and NLR were 0.38 and 3.14, respectively. High CRP/Alb ratio (≥0.38) and NLR (≥3.14) values were associated with increased tumor invasion, more distant metastasis and a more advanced tumor-node-metastasis stage (all P<0.05). In addition, a high NLR value was also associated with increased tumor size (P=0.02). The CRP/Alb ratio (≥0.38/<0.38) and NLR (≥3.14/<3.14) were independent prognostic factors for overall survival time (OS) in GC by multivariate analysis (P=0.005 and P=0.001). Using the CRP/Alb ratio and NLR classification, patients were stratified into three subgroups with different OS time (P<0.001), which were identified as independent prognostic variables in multivariate analysis (P<0.001). The present study demonstrated that the CRP/Alb ratio and NLR were independent prognostic factors for OS in patients with GC. The combination of these indexes was associated with significant prognostic value and may further stratify prognosis.

Entities:  

Keywords:  C-reactive protein; albumin; gastric cancer; lymphocyte; neutrophil; prognosis

Year:  2017        PMID: 29344182      PMCID: PMC5755031          DOI: 10.3892/ol.2017.7179

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  52 in total

1.  Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin disease.

Authors:  Ben A Croker; Rowena S Lewis; Jeff J Babon; Justine D Mintern; Dieter E Jenne; Donald Metcalf; Jian-Guo Zhang; Louise H Cengia; Joanne A O'Donnell; Andrew W Roberts
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.

Authors:  Hiroaki Nozawa; Christopher Chiu; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-04       Impact factor: 11.205

Review 4.  Targeted therapies in gastric cancer treatment: where we are and where we are going.

Authors:  Gianluca Tomasello; Michele Ghidini; Wanda Liguigli; Margherita Ratti; Laura Toppo; Rodolfo Passalacqua
Journal:  Invest New Drugs       Date:  2016-02-12       Impact factor: 3.850

5.  Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients.

Authors:  Michel Carlos Mocellin; Juliana de Aguiar Pastore e Silva; Carolina de Quadros Camargo; Maria Emília de Souza Fabre; Scheila Gevaerd; Katya Naliwaiko; Yara Maria Franco Moreno; Everson Araújo Nunes; Erasmo Benicio Santos de Moraes Trindade
Journal:  Lipids       Date:  2013-07-26       Impact factor: 1.880

6.  Inflammatory models drastically alter tumor growth and the immune microenvironment in hepatocellular carcinoma.

Authors:  Geoffrey J Markowitz; Gregory A Michelotti; Anna Mae Diehl; Xiao-Fan Wang
Journal:  Sci Bull (Beijing)       Date:  2015-04-01       Impact factor: 11.780

7.  Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Kristina A Williams; S Intidhar Labidi-Galy; Kathryn L Terry; Allison F Vitonis; William R Welch; Annekathryn Goodman; Daniel W Cramer
Journal:  Gynecol Oncol       Date:  2014-01-23       Impact factor: 5.482

8.  Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer.

Authors:  Mitsuru Ishizuka; Hitoshi Nagata; Kazutoshi Takagi; Yoshimi Iwasaki; Norisuke Shibuya; Keiichi Kubota
Journal:  Ann Surg Oncol       Date:  2015-11-03       Impact factor: 5.344

9.  A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio.

Authors:  Xiao-li Wei; Feng-hua Wang; Dong-sheng Zhang; Miao-zhen Qiu; Chao Ren; Ying Jin; Yi-xin Zhou; De-shen Wang; Ming-ming He; Long Bai; Feng Wang; Hui-yan Luo; Yu-hong Li; Rui-hua Xu
Journal:  BMC Cancer       Date:  2015-05-02       Impact factor: 4.430

Review 10.  Systemic Inflammatory Response Based on Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Bladder Cancer.

Authors:  Hyung Suk Kim; Ja Hyeon Ku
Journal:  Dis Markers       Date:  2016-01-05       Impact factor: 3.434

View more
  13 in total

1.  Serum C-Reactive Protein/Albumin Ratio in Rheumatoid Arthritis and its Relationship With Disease Activity, Physical Function, and Quality of Life.

Authors:  İsmihan Sunar; Şebnem Ataman
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

2.  Cross sectional association between cytomegalovirus seropositivity, inflammation and cognitive impairment in elderly cancer survivors.

Authors:  Sithara Vivek; Heather Hammond Nelson; Anna E Prizment; Jessica Faul; Eileen M Crimmins; Bharat Thyagarajan
Journal:  Cancer Causes Control       Date:  2021-10-12       Impact factor: 2.506

3.  The C-reactive protein to albumin ratio predicts postoperative complication in patients who undergo gastrectomy for gastric cancer.

Authors:  Jin Won Lee; Ashish Ranjan Sharma; Sang-Soo Lee; Wan Joo Chun; Hae Sung Kim
Journal:  Heliyon       Date:  2020-06-15

4.  Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis.

Authors:  Mi-Rae Kim; A-Sol Kim; Hye-In Choi; Jae-Hun Jung; Ji Yeon Park; Hae-Jin Ko
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

5.  Relationship of Red Blood Cell Distribution Width with Cancer Mortality in Hospital.

Authors:  Jinmeng Li; Xiaoning Yang; Junfeng Ma; Fanghua Gong; Qiongzhen Chen
Journal:  Biomed Res Int       Date:  2018-11-14       Impact factor: 3.411

6.  Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis.

Authors:  Yi Zhang; Guoliang Xiao; Rong Wang
Journal:  Cancer Manag Res       Date:  2019-05-07       Impact factor: 3.989

7.  Prognostic Value of the Combination of CEA and Fibrinogen/Albumin Ratio in Resectable Gastric Cancer.

Authors:  Junbin Zhang; Jiayin Ruan; Weibin Wang; Yimin Lu; Haiyong Wang; Xiongfei Yu; Haohao Wang; Lisong Teng
Journal:  Cancer Manag Res       Date:  2020-04-23       Impact factor: 3.989

8.  Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer.

Authors:  Qian Yu; Ke-Zhi Li; Yan-Jun Fu; Yanping Tang; Xin-Qiang Liang; Zhi-Qing Liang; Ji-Hong Bai
Journal:  Ann Surg Treat Res       Date:  2021-06-01       Impact factor: 1.859

9.  Prognostic role of the pretreatment C-reactive protein/albumin ratio in gastric cancer: A systematic review and meta-analysis.

Authors:  Xuanxuan Yang; Xing Song; Luo Zhang; Changping Wu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

10.  The C-Reactive Protein/Albumin Ratio as a Predictor of Mortality in Critically Ill Patients.

Authors:  Ji Eun Park; Kyung Soo Chung; Joo Han Song; Song Yee Kim; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Moo Suk Park; Young Sam Kim; Joon Chang; Ah Young Leem
Journal:  J Clin Med       Date:  2018-10-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.